Axon 3013
CAS [86780-90-7]
MF C19H20N2O7MW 388.37
Calcium antagonist with potent and long-lasting vasodilating and antihypertensive activities.
KEYWORDS: Aranidipine | supplier | Ca channel antagonist | MPC-1304 | Sapresta | MPC1304 | MPC 1304 | CAS [86780-90-7] | Calcium | Non Selective | Antagonist | Ion Channels | Hypertension | Angino pectoris
A Kanda et al. Cardiovascular profile of MPC-1304, a novel dihydropyridine calcium antagonist: comparison with other calcium antagonists. J Cardiovasc Pharmacol. 1993 Jul;22(1):167-75. |
K Miyoshi et al. MPC-1304, another type of dihydropyridine, possessing highly potent vasodilating action. Eur J Pharmacol. 1993 Jul 20;238(2-3):139-48. |
S Ohno et al. Synthesis of asymmetric 4-aryl-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylates with vasodilating and antihypertensive activities. Chem Pharm Bull (Tokyo). 1986 Apr;34(4):1589-606. |
3-Methyl 5-(2-oxopropyl) 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
[86780-90-7]
Axon Medchem的业务之一,是独有的Axon Ligands配体库,在世界范围内,被认为是药物研发的标准。这其中,针对850余种生物靶标(包括细胞信号、基因转录、凋亡、细胞周期调控、CNS等),Axon Medchem拥有多达2000余种小分子抑制剂或调节剂。除了配体库,Axon Medchem还是欧洲著名的CRO公司,主要针对生物活性分子和药物类似分子展开合成及协议开发工作,在过去的10年中,Axon Medchem已经发现了多种潜在药物分子,并在生物医药界享有一定的声誉。